1.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16-00017, NCT00754468
|
|
3.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-13, NCT00911092
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: AGIM-1, NCT01038154
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: JACCRO GC-05, NCT00639327
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FRE-FNCLCC- ACCORD-17/0707, FRE-FNCLCC- ACCORD-17/0707, EU-20848, NCT00861094
|
|
8.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TROG 03.01, NCIC CTG ES.2, TGA 2004/83, NHMRC 291103, NCT00193882
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0436, RTOG 0436, NCT00655876
|
|
10.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 to 81
Sponsor: Other
Protocol IDs: E3.30.27, NCT00665197
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 200048-052, NCT00678535
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF110656, EGF110656-TRIO-CIRG 013, NCT00680901
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 0806009855, NCT00760604
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CCR3024, NCT00824785
|
|
15.
|
Phase: Phase III
Type: Health services research, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRCA-COUGAR-02, COUGAR-02, EudraCT-2006-005046-37, ISRCTN13366390, CRUK/07/013, EU-20969, NCT00978549
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: HGCSG0305-2, TPF-2, NCT00209716
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: HGCSG0305-1, TPF, NCT00209690
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: VU-VICC-GI-0622, VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0445, NCT00492817
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTCT 06-11, NCT00493883
|
|
21.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-446, NCT00508443
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: FFCD-0505, FFCD-0505, EU-20756, EUDRACT-2006-004770-27, MERCK-FFCD-0505, NCT00544362
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 82
Sponsor: Other
Protocol IDs: Pro00002207, SPS 151596, NCT00578071
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 07326, NCT00667420
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: WEUTC, NCT00669292
|
